Sie suchten nach: daronrix (Englisch - Maltesisch)

what is daronrix?
x’inhu daronrix?

how does daronrix work?
kif jaħdem daronrix?

daronrix is a vaccine.
daronrix huwa vaċċin.

how has daronrix been studied?
kif ġie studjat daronrix?

other information about daronrix:
tagħrif ieħor dwar daronrix:

what is the risk associated with daronrix?
x’inhu r-riskju assoċjat ma’ daronrix?

daronrix is a ‘mock-up’ vaccine.
daronrix huwa vaċċin ‘prova’.

the full epar for daronrix can be found here.
l-epar sħiħ dwar daronrix jista’ jinstab hawnhekk.

what information is still awaited for daronrix?
x’tagħrif għad hemm bżonn għal daronrix?

what benefit has daronrix shown during the studies?
x’benefiċċji wera daronrix matul l-istudji?

daronrix has been authorised under “exceptional circumstances”.
daronrix ġie awtorizzat taħt “Ċirkustanza ta’ eċċezzjoni”.

daronrix contains small amounts of a virus called h5n1.
daronrix fih ammonti żgħar ta’ virus imsejjaħ h5n1.

daronrix is given in two doses, at least three weeks apart.
daronrix jingħata f’żewġ dożi, għallinqas tliet ġimgħat ’il bogħod minn xulxin.

for the full list of all side effects reported with daronrix, see the package leaflet.
għal-lista sħiħa ta’ l-effetti sekondarji rrapportati b’daronrix, ara l-fuljett ta’ tagħrif.

the effects of daronrix were first tested in experimental models before being studied in humans.
l-effetti ta’ daronrix ġew ittestjati l-ewwel f’mudelli esperimentali qabel ma ġie studjat fuq il- bniedem.

the study showed that daronrix containing 15 micrograms of haemagglutinin and the adjuvant produced an antibody response that satisfies these criteria.
l-istudju wera li daronrix li fih 15-il mikrogramm ta’ haemagglutinin u l-adjuvant ipproduċa rispons ta’ antikorpi li jissodisfa dawn il-kriterji.

if a pandemic starts, the virus strain in daronrix will be replaced by the strain causing the pandemic before the vaccine can be used.
jekk tibda l-pandemija, ir- razza tal-virus f’daronrix tiġi sostitwita bir-razza li tikkawża l-pandemija qabel jintuża l-vaċċin.

if daronrix is used during a pandemic, the company that makes it will collect information on the safety of the vaccine while it is being used.
jekk daronrix jintuża matul pandemija, il-kumpanija li tagħmlu, tiġbor tagħrif fuq is-sigurtà tal-vaċċin filwaqt li jkun qiegħed jintuża.

if a pandemic is declared, and if the company that makes daronrix decides to market the vaccine, they will include the flu strain responsible in the vaccine.
jekk tiġi iddikjarata pandemija, u jekk il-kumpanija li tagħmel daronrix tiddeċiedi li tpoġġi l-vaċċin fis-suq, ir-razza ta’ l-influwenza responsabbli se tiġi nkluża fil-vaċċin.

the chmp concluded that daronrix’s benefits outweighed its risks, and that it had shown its suitability as a mock-up vaccine in preparation for a pandemic flu outbreak.
il-chmp ikkonkluda li l-benefiċċji ta’ daronrix jisbqu r-riskji tiegħu, u li daronrix wera l- adegwatezza tiegħu bħala vaċċin prova fi tħejjija għal tifqigħa ta’ l-influwenza pandemika.